Celcuity Inc. (CELC) shares went up by 4.87% to trade at $29.3 in after-market at the time of writing. CELC stock closed Monday’s session at $27.94 which is a 29.35% gain. The CELC stock volume traded around 4.86 million shares, which was higher than the average daily volume of 0.46 million shares within the past 50 days
What is the recent news on Cecluity’s operational activities?
On 12th April, Celcuity participated in the American Association for Cancer Research (AACR) Annual Meeting and there presented the outcomes of its studies which evaluated gedatolisib, inavolisib, and navitoclax in breast and ovarian patient tumors. Gedatolisib is a pan-P13K/mTOR inhibitor, inavolisib is a P13K-α inhibitor and navitoclax is a BCL inhibitor. Two e-posters were used by the company for the presentation of these studies and result.
Results and characteristics of the study
The posters presented the use of CELsignia test to characterize the role of RAS network nodes; CELsignia RAS Network Activity test that is used by the company identifies hyperactive RAS network signal done by the ovarian or breast cancer patients’ tumors. Furthermore, CELsignia also characterizes gedatolisib, inavolisib, navitoclax as well as RAS signaling role in the phospholipid-initiated signaling activity that is done through the lysophosphatidic acid (LPA) receptor family of GPCRs in the tumor cells and cell lines of ovarian and breast cancer patients.
The results of these studies indicated that there is a potential advantage of not just inhibiting P13k-α signaling but inhibiting all Class 1 P13K isoforms as well as mTOR for treating P13K signaling tumors.
Licensing agreement with pharma-giant Pfizer
The CELC stock soared more than 50% on 9th April after it announced a licensing agreement with the world-renowned pharma-company Pfizer PFE. In the agreement, Celcuity paid $10 million to Pfizer in upfront payment as per the terms and Pfizer will receive up to $330 million in development and sales-based milestone from Celcuity along with royalties on future sales.
Furthermore, Celcuity also announced a promise to present the preliminary data on the recent ongoing phase 1b study evaluating gedatolisib in combination with Pfizer’s Ibrance as well as an endocrine therapy in Er+/HER2 – advanced or metastatic breast cancer patients. Phase II/III study of gedatolisib with the pfixer combo is expected to start in mid of 2022.
Insight on Celcuity’s overall background
Celcuity is a clinical stage biotechnology company that is specifically creating novel therapies and treatments in a unique and innovative approach towards cancer treatments. The company is differentiated based on its focus on creating integrated companion diagnostics and therapeutic strategy for cancer patients. The objective of this focus is to enhance and extend the lives of cancer patients.
The companion diagnostics is able to identify the cancer driver in the patient and then the therapeutic efforts target the cancer driver molecularly. The proprietary diagnostic platform of CELC stock is known as CELsignia which has the tech-ability to analyze the live tumor cells that then identify new groups of cancer patients for whom targeted therapies are favorable. This diagnosis is furthered by CELsigniaCDx that supports the advancement new developing indications for the established targeted therapies.
Based on this therapeutic strategy and integrated companion diagnostic, Celcuity is positioned in the cancer treatment and therapy market uniquely to treat the cancer driver in the most suited way possible for the patients.